Get the Stockscreener App
4.21
4.10%
-0.18
After Hours:
4.28
0.07
+1.66%
Aptevo Therapeutics Inc stock is traded at $4.21, with a volume of 37,978.
It is down -4.10% in the last 24 hours and down -7.47% over the past month.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, CD3xCD123, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.
See More
Previous Close:
$4.39
Open:
$4.38
24h Volume:
37,978
Relative Volume:
0.72
Market Cap:
$5.25M
Revenue:
$12.99M
Net Income/Loss:
$-27.83M
P/E Ratio:
-0.0207
EPS:
-203.7366
Net Cash Flow:
$-26.98M
1W Performance:
-11.46%
1M Performance:
-7.47%
6M Performance:
-49.03%
1Y Performance:
-92.36%
1-Day Range:
$4.1684
$4.45
1-Week Range:
$4.1684
$4.61
52-Week Range:
$3.6803
$55.26
Aptevo Therapeutics Inc Stock (APVO) Company Profile
Name
Aptevo Therapeutics Inc
Sector
Industry
Phone
206-838-0500
Address
2401 4TH AVE., SEATTLE, WA
Compare APVO vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
APVO
Aptevo Therapeutics Inc
|
4.21 | 5.47M | 12.99M | -27.83M | -26.98M | -203.74 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Aptevo Therapeutics Inc Stock (APVO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-05-18 | Initiated | Ladenburg Thalmann | Buy |
| Oct-05-17 | Resumed | Piper Jaffray | Overweight |
Aptevo Therapeutics Inc Stock (APVO) Latest News
Aptevo Therapeutics Unveils New Solid Tumor Strategy - TipRanks
Aptevo files patent for Nectin-4 x PD-L1 cancer platform - Investing.com
Aptevo Filing May Support Radiopharmaceuticals and T-Cell Engagers - Stock Titan
Aptevo Therapeutics Inc (APVO) Cash Flow - TradingKey
Aptevo Therapeutics Inc (APVO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Aptevo Therapeutics Inc (APVO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
APVO|Aptevo Therapeutics Inc|Price:4.390|Chg%:+0.020 - TradingKey
TradingKey - TradingKey
Aptevo Therapeutics Inc. Revenue Breakdown – NASDAQ:APVO - TradingView
Aptevo Therapeutics Inc (APVO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Mary Jo Janatpour Net Worth (2026) - GuruFocus
Niowave, Inc. Net Worth (2026) - GuruFocus
Aptevo Therapeutics Inc (APVO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Aptevo Therapeutics (APVO) Edges Higher: Testing Key Resistance Amid Steady VolumeBPI Reversal - dars.gov.et
Aptevo Therapeutics Secures Grant for APVO451 Development - The Globe and Mail
Grant supports Aptevo’s immunotherapy APVO-451 for solid tumors - BioWorld News
Aptevo (NASDAQ: APVO) gets $1.5M CARE Fund grant to advance APVO451 - Stock Titan
Aptevo receives $1.5M grant for cancer therapy development - Investing.com
Aptevo Secures $1.5 Million Non-Dilutive Research Grant From the Andy Hill Care Fund to Advance APVO451, a Nectin-4-Targeted Trispecific Immunotherapy for Solid Tumors - The Joplin Globe
Aptevo gets $1.5M grant to advance a trispecific cancer drug - Stock Titan
Price to sales forward of Aptevo Therapeutics Inc. – NASDAQ:APVO - TradingView
Price to sales forward of Aptevo Therapeutics, Inc. – MUN:AP82 - TradingView
Aptevo Therapeutics (APVO) Edges Lower, Testing Key Support LevelsFlat Correction - dars.gov.et
Price to book forward of Aptevo Therapeutics Inc. – NASDAQ:APVO - TradingView
APVO Forecast — Price Target — Prediction for 2027 - TradingView
Price to earnings forward of Aptevo Therapeutics Inc. – NASDAQ:APVO - TradingView
Enterprise value to EBIT forward of Aptevo Therapeutics Inc. – NASDAQ:APVO - TradingView
Price to earnings forward of Aptevo Therapeutics, Inc. – MUN:AP82 - TradingView
Aptevo Therapeutics, Inc. Actuals & Estimates (NASDAQ:APVO) - TradingView
Aptevo Therapeutics, Inc. Actuals & Estimates (MUN:AP82) - TradingView
Aptevo Therapeutics (APVO) Gains 2.73% as Shares Test Key Resistance Near $4.95ETF Creation Redemption - dars.gov.et
Aptevo Therapeutics, Inc. Actuals & Estimates (FWB:AP82) - TradingView
AP82 Forecast — Price Target — Prediction for 2027 - TradingView
Aptevo Therapeutics Inc (APVO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Form 13G Aptevo Therapeutics Inc. For: 22 June By Investing.com - Investing.com South Africa
Niowave holds 12.18% of Aptevo (NASDAQ: APVO) — 151,723 shares - Stock Titan
NIOWAVE, INC. (NASDAQ: APVO) discloses 98,522 shares and $8 warrants - Stock Titan
Aptevo Therapeutics Inc (APVO) Valuation: PE, PB & Fair Value Analysis - TradingKey
Aptevo Therapeutics Inc (APVO) Institutional Confidence - TradingKey
Aptevo Therapeutics Inc (APVO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Aptevo Therapeutics Inc (APVO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Aptevo and Niowave Partner to Advance Radiopharmaceutical Cancer Therapies - citybuzz -
As Big Pharma Bets On Radiopharmaceuticals, Aptevo And Niowave Join Forces To Advance Novel Targeted Cancer Therapeutics In The $17B+ Oncology Category - NewMediaWire
Aptevo reports 87% clinical benefit rate in AML trial - Investing.com
- The Legal Advocate
Aptevo Therapeutics (APVO) Slips 1.43% as Shares Approach Support at $4.66Volume Climax - dars.gov.et
Aptevo Therapeutics (APVO) Slips 1.43% as Shares Test Key Support Near $4.66Butterfly Setup - The Legal Advocate
Aptevo Therapeutics (APVO) Holds Near Support After Modest DeclineHedge Fund Favorites - dars.gov.et
Aptevo Therapeutics Dip Continues as Stock Consolidates Near Key SupportBuffered ETF - The Legal Advocate
Aptevo Therapeutics (APVO) Slides Lower as Support Level Comes Into FocusFibonacci Retracement - The Legal Advocate
Aptevo Therapeutics (APVO) SVP, CSO files Form 3 reporting zero shares - Stock Titan
Aptevo Therapeutics Inc Stock (APVO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):